Cardiotoxicity of BTK inhibitors: ibrutinib and beyond
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2067526
Abstract: ABSTRACT Introduction The development of Brutons Tyrosine Kinase (BTK) inhibitors has transformed the treatment of B-cell malignancies and other non-malignant conditions. Management of the unique cardiotoxic profile of these agents requires prompt recognition and a… read more here.
Keywords: btk inhibitor; btk; cardiotoxicity btk; inhibitors ibrutinib ... See more keywords